| __timestamp | Agios Pharmaceuticals, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 6620800000 |
| Thursday, January 1, 2015 | 35992000 | 6533000000 |
| Friday, January 1, 2016 | 50714000 | 6452000000 |
| Sunday, January 1, 2017 | 71124000 | 6588100000 |
| Monday, January 1, 2018 | 114145000 | 5975100000 |
| Tuesday, January 1, 2019 | 132034000 | 6213800000 |
| Wednesday, January 1, 2020 | 149070000 | 6121200000 |
| Friday, January 1, 2021 | 121445000 | 6431600000 |
| Saturday, January 1, 2022 | 121673000 | 6440400000 |
| Sunday, January 1, 2023 | 119903000 | 6941200000 |
| Monday, January 1, 2024 | 156784000 | 8593800000 |
Cracking the code
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Eli Lilly and Company and Agios Pharmaceuticals, Inc. from 2014 to 2023.
Eli Lilly, a giant in the industry, consistently allocated a significant portion of its budget to SG&A, averaging around $6.4 billion annually. This investment underscores its commitment to maintaining a robust market presence and operational efficiency. In contrast, Agios Pharmaceuticals, a smaller entity, exhibited a more dynamic growth in SG&A expenses, increasing from approximately $19 million in 2014 to $120 million in 2023. This represents a staggering 530% increase, reflecting its aggressive expansion and market penetration strategies.
The data highlights the contrasting financial strategies of these companies, offering insights into their operational priorities and market positioning.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Amgen Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs argenx SE Trends and Insights
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Eli Lilly and Company or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Alpine Immune Sciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Arrowhead Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.